-
公开(公告)号：US10548964B2
公开(公告)日：2020-02-04
申请号：US15964211
申请日：2018-04-27
Applicant: SENTINEXT THERAPEUTICS Sdn Bhd
Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.
-
公开(公告)号：US20150140027A1
公开(公告)日：2015-05-21
申请号：US14402495
申请日：2012-11-01
Applicant: SENTINEXT THERAPEUTICS Sdn Bhd
IPC: A61K39/125 , C12N7/00
CPC classification number: A61K39/125 , A61K39/12 , A61K39/13 , A61K2039/5256 , A61K2039/5258 , A61K2039/70 , C12N7/00 , C12N2710/14043 , C12N2770/32323 , C12N2770/32334 , C12N2770/32351 , C12N2770/32371 , C12N2770/32634 , Y02A50/466
Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.
-
公开(公告)号：US20190247488A1
公开(公告)日：2019-08-15
申请号：US16339520
申请日：2017-09-21
Applicant: SENTINEXT THERAPEUTICS Sdn Bhd
Inventor： Mary Jane CARDOSA
IPC: A61K39/125 , A61P31/14 , C12N15/85
CPC classification number: A61K39/125 , A61K39/135 , A61P31/14 , C12N15/85 , C12N2710/10323 , C12N2770/32334 , C12N2770/32371 , Y02A50/466
Abstract: This invention relates to Virus-Like Particles (VLPs) derived from Enterovirus and vaccines comprising such VLPs which elicit immune responses and/or protective neutralizing antibody responses directed against an Enterovirus. The instant invention provides expression cassettes and methods for making Enterovirus CV-A16 VLPs and compositions enriched in CV-A16 VLPs which exhibit conformational epitopes which elicit immune responses and/or neutralizing antibody responses which may be used in vaccines directed against Enterovirus CV-A16.
-
公开(公告)号：US09987350B2
公开(公告)日：2018-06-05
申请号：US14402495
申请日：2012-11-01
Applicant: SENTINEXT THERAPEUTICS Sdn Bhd
CPC classification number: A61K39/125 , A61K39/12 , A61K39/13 , A61K2039/5256 , A61K2039/5258 , A61K2039/70 , C12N7/00 , C12N2710/14043 , C12N2770/32323 , C12N2770/32334 , C12N2770/32351 , C12N2770/32371 , C12N2770/32634 , Y02A50/466
Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human Enterovirus B, Human enterovirus C, Human Enterovirus D antigens and their use in vaccines for the prevention of an enterovirus infection.
-
Patent Agency Ranking
公开(公告)号：US20180271971A1
公开(公告)日：2018-09-27
申请号：US15964198
申请日：2018-04-27
Applicant: SENTINEXT THERAPEUTICS Sdn Bhd
IPC: A61K39/125 , C12N7/00 , A61K39/12 , A61K39/13 , A61K39/00
CPC classification number: A61K39/125 , A61K39/12 , A61K39/13 , A61K2039/5256 , A61K2039/5258 , A61K2039/70 , C12N7/00 , C12N2710/14043 , C12N2770/32323 , C12N2770/32334 , C12N2770/32351 , C12N2770/32371 , C12N2770/32634 , Y02A50/466
Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.
-
公开(公告)号：US20180243400A1
公开(公告)日：2018-08-30
申请号：US15964211
申请日：2018-04-27
Applicant: SENTINEXT THERAPEUTICS Sdn Bhd
IPC: A61K39/125 , C12N7/00 , A61K39/12 , A61K39/13 , A61K39/00
CPC classification number: A61K39/125 , A61K39/12 , A61K39/13 , A61K2039/5256 , A61K2039/5258 , A61K2039/70 , C12N7/00 , C12N2710/14043 , C12N2770/32323 , C12N2770/32334 , C12N2770/32351 , C12N2770/32371 , C12N2770/32634 , Y02A50/466
Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.
-
公开(公告)号：US10555997B2
公开(公告)日：2020-02-11
申请号：US15964198
申请日：2018-04-27
Applicant: SENTINEXT THERAPEUTICS Sdn Bhd
Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.
-
公开(公告)号：US20190224304A1
公开(公告)日：2019-07-25
申请号：US16339772
申请日：2017-09-21
Applicant: SENTINEXT THERAPEUTICS Sdn Bhd
Inventor： Mary Jane CARDOSA
IPC: A61K39/125 , A61K39/13 , A61K39/135
Abstract: The invention provides chimeric Enterovirus virus-like particles (VLPs) for protection and/or treatment against infection by more than one Enterovirus. More specifically, the present invention provides chimeric EV-A71 virus-like particles displaying CV-A16 VP1 polypeptides and at the same time maintaining important neutralizing antibody epitopes of EV-A71 itself. More specifically, the present invention provides chimeric CV-A16 virus-like particles displaying EV-A71 VP1 polypeptides. Thus, the present invention provides a bivalent vaccine comprising the chimeric virus-like particles which elicit an immune response and/or neutralizing antibody response to both EV-A71 and CVA-16 for the treatment of Hand, Foot and Mouth Disease.
-
公开(公告)号：US20150056244A1
公开(公告)日：2015-02-26
申请号：US14464472
申请日：2014-08-20
Applicant: Sentinext Therapeutics Sdn Bhd
IPC: A61K39/125 , C12N7/00
CPC classification number: C12N7/00 , A61K39/12 , C07K14/005 , C12N15/86 , C12N2710/14143 , C12N2770/32322 , C12N2770/32323 , C12N2770/32334 , C12N2770/32351 , C12N2840/203 , Y02A50/466
Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.
Abstract translation: 本发明提供了用于产生衍生自小核糖核酸病毒科病毒家族成员的免疫活性抗原的材料和方法。 本发明的小核糖核酸病毒抗原可以是用于在治疗性治疗中施用于受试者的疫苗或用于预防小RNA病毒感染的形式。 本发明的小核糖核酸病毒抗原可以是用于疫苗的免疫原性组合物的形式，其用于预防肠道病毒感染。 本发明还包括包含人肠道病毒A，人肠道病毒B，人肠病毒C，人肠道病毒D抗原及其在疫苗中用于预防肠道病毒感染的应用的免疫原性组合物。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.015 seconds)
